FY2021 Earnings Forecast for Lonza Group Ltd (OTCMKTS:LZAGY) Issued By KeyCorp

Lonza Group Ltd (OTCMKTS:LZAGY) – Equities researchers at KeyCorp decreased their FY2021 earnings estimates for shares of Lonza Group in a research report issued to clients and investors on Tuesday, October 12th. KeyCorp analyst P. Knight now forecasts that the company will post earnings per share of $1.42 for the year, down from their prior forecast of $1.44. KeyCorp also issued estimates for Lonza Group’s FY2022 earnings at $1.59 EPS and FY2023 earnings at $1.80 EPS.

Several other brokerages have also recently commented on LZAGY. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Lonza Group in a research report on Wednesday, September 8th. Societe Generale reaffirmed a “buy” rating on shares of Lonza Group in a research note on Thursday, July 29th. Morgan Stanley downgraded shares of Lonza Group from an “overweight” rating to an “equal weight” rating in a research report on Friday, September 17th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Lonza Group in a research report on Thursday, July 29th. Finally, Citigroup restated a “neutral” rating on shares of Lonza Group in a report on Wednesday, July 28th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $91.00.

OTCMKTS:LZAGY opened at $77.96 on Thursday. The firm has a 50-day moving average of $80.39 and a two-hundred day moving average of $71.56. The stock has a market cap of $58.06 billion, a P/E ratio of 59.97 and a beta of 0.62. Lonza Group has a 1-year low of $55.69 and a 1-year high of $86.31.

Lonza Group Company Profile

Lonza Group AG engages in the supply of pharmaceutical, healthcare and life science products. It operates through the following segments: Lonza Pharma Biotech & Nutrition and Lonza Specialty Ingredients. The Pharma Biotech & Nutrition segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems.

See Also: Why is cost of goods sold important?

Earnings History and Estimates for Lonza Group (OTCMKTS:LZAGY)

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.